NASDAQ:EBIO - Eleven Biotherapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.29 +0.64 (+24.15 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$3.29
Today's Range$2.73 - $3.44
52-Week Range$0.62 - $3.50
Volume15.58 million shs
Average Volume2.86 million shs
Market Capitalization$159.20 million
P/E Ratio-2.96
Dividend YieldN/A
Eleven Biotherapeutics logoEleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive EBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.88
Quick Ratio3.17


Trailing P/E Ratio-2.96
Forward P/E Ratio-6.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$430,000.00
Price / Sales365.65
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book6.71


EPS (Most Recent Fiscal Year)($1.11)
Net Income$-29,020,000.00
Net MarginsN/A
Return on Equity-126.96%
Return on Assets-33.38%


Outstanding Shares47,790,000

Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics (NASDAQ:EBIO) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.

What price target have analysts set for EBIO?

2 brokerages have issued 12-month target prices for Eleven Biotherapeutics' stock. Their predictions range from $2.00 to $8.00. On average, they expect Eleven Biotherapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Eleven Biotherapeutics.

Are investors shorting Eleven Biotherapeutics?

Eleven Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totalling 6,739,239 shares, an increase of 48.5% from the April 30th total of 4,536,882 shares. Based on an average daily volume of 6,663,859 shares, the short-interest ratio is presently 1.0 days. View Eleven Biotherapeutics' Current Options Chain.

Who are some of Eleven Biotherapeutics' key competitors?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:
  • Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
  • Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 59)
  • Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board

Has Eleven Biotherapeutics been receiving favorable news coverage?

Press coverage about EBIO stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Eleven Biotherapeutics' major shareholders?

Eleven Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (7.40%), SABBY MANAGEMENT, LLC (7.40%), Highbridge Capital Management LLC (3.33%), Sabby Management LLC (2.57%) and Millennium Management LLC (0.51%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.

Which institutional investors are buying Eleven Biotherapeutics stock?

EBIO stock was purchased by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Sabby Management LLC and Millennium Management LLC. View Insider Buying and Selling for Eleven Biotherapeutics.

How do I buy shares of Eleven Biotherapeutics?

Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' stock price today?

One share of EBIO stock can currently be purchased for approximately $3.29.

How big of a company is Eleven Biotherapeutics?

Eleven Biotherapeutics has a market capitalization of $159.20 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.

How can I contact Eleven Biotherapeutics?

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]

MarketBeat Community Rating for Eleven Biotherapeutics (EBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.